Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ARTL

Artelo Biosciences Inc

Dec 11 • 04:00PM ET

1.10

Dollar change -0.01
Percentage change -0.90	%

Healthcare • Biotechnology • USA • NASD

Peers: CLSD ONCY MEIP EPIX MBIO MTNB BPTH PULM VSTM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.84	Insider Own	0.83%	Shs Outstand	3.23M	Perf Week	0.00%
Market Cap	3.55M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	0.00%	Shs Float	3.20M	Perf Month	-11.08%
Income	-9.12M	PEG	-	EPS next Q	-0.44	Inst Own	0.70%	Short Float	1.03%	Perf Quarter	-5.18%
Sales	0.00M	P/S	-	EPS this Y	37.26%	Inst Trans	-11.75%	Short Ratio	1.30	Perf Half Y	-17.29%
Book/sh	1.97	P/B	0.56	EPS next Y	54.15%	ROA	-80.59%	Short Interest	0.03M	Perf Year	-22.54%
Cash/sh	1.51	P/C	0.73	EPS next 5Y	-	ROE	-87.12%	52W Range	1.00 - 1.75	Perf YTD	-21.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.34%	ROI	-141.65%	52W High	-37.14%	Beta	1.27
Dividend TTM	-	Quick Ratio	7.15	Sales past 5Y	0.00%	Gross Margin	-	52W Low	10.00%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	7.15	EPS Y/Y TTM	14.28%	Oper. Margin	-	RSI (14)	47.30	Volatility	14.56% 9.62%
Employees	6	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	5.33
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	57.77%	Payout	-	Rel Volume	0.90	Prev Close	1.11
Sales Surprise	-	EPS Surprise	55.84%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	25.36K	Price	1.10
SMA20	-1.06%	SMA50	-3.65%	SMA200	-15.34%	Trades		Volume	22,938	Change	-0.90%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-21	Initiated	Ladenburg Thalmann	Buy	$7

Dec-10-24 09:43AM	Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia (TipRanks)
Dec-09-24 09:15AM	Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia (GlobeNewswire) -5.39%
Nov-18-24 08:30AM	Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit (GlobeNewswire) +17.31%
Nov-13-24 08:30AM	Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium (GlobeNewswire) -5.98%
Nov-12-24 08:00AM	Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.42%
08:30AM	Loading…
Nov-05-24 08:30AM	Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's Preclinical Screening Platform for Pain Program (GlobeNewswire) +9.66%
Oct-09-24 09:00AM	Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th (GlobeNewswire)
Sep-04-24 09:00AM	Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 08:00AM	Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-15-24 08:30AM	Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor (GlobeNewswire)
Jul-03-24 09:00AM	Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jul-02-24 09:00AM	Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform (GlobeNewswire)
Jul-01-24 09:00AM	Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-04-24 08:30AM	Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society (GlobeNewswire)
May-29-24 08:30AM	Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24 (GlobeNewswire)
01:53PM	Loading…
May-13-24 01:53PM	ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-10-24 09:00AM	Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th (GlobeNewswire)
Apr-23-24 08:30AM	Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy (GlobeNewswire)
Apr-22-24 08:30AM	Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time (GlobeNewswire)
Mar-25-24 01:53PM	ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023 (InvestorPlace)
08:00AM	Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 09:15AM	Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge (GlobeNewswire)
Feb-15-24 09:00AM	Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th (ACCESSWIRE) +6.13%
Jan-23-24 08:30AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy (GlobeNewswire)
Jan-08-24 08:30AM	Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12 (GlobeNewswire)
Dec-05-23 08:30AM	Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany (GlobeNewswire)
Nov-30-23 09:00AM	Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany (GlobeNewswire)
Nov-13-23 08:00AM	Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-23 09:00AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers (GlobeNewswire) -8.33%
08:30AM	Loading…
Nov-02-23 08:30AM	Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023 (GlobeNewswire)
Oct-04-23 08:30AM	Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia (GlobeNewswire)
Sep-13-23 08:30AM	Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th (GlobeNewswire)
Sep-07-23 08:00AM	Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12 (GlobeNewswire) -22.60%
Sep-06-23 09:00AM	Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th (GlobeNewswire) +27.03%
Sep-05-23 09:00AM	Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th (GlobeNewswire)
Aug-10-23 08:00AM	Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-19-23 09:00AM	Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023 (GlobeNewswire)
Jul-10-23 08:30AM	Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11 (GlobeNewswire)
Jun-28-23 08:30AM	Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-27-23 08:30AM	Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-26-23 08:30AM	Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-07-23 08:30AM	Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire) +10.26%
May-11-23 08:00AM	Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-23 08:30AM	Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire) -21.75%
Mar-31-23 08:00AM	Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update (GlobeNewswire) +7.91%
Feb-15-23 08:30AM	Artelo Biosciences to Present at MicroCap Rodeos Annual Winter Wonderland Best Ideas Virtual Investor Conference on February 22, 2023 (ACCESSWIRE)
Feb-02-23 09:00AM	Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire)
Jan-26-23 08:30AM	Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd (GlobeNewswire)
Nov-08-22 08:00AM	Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-18-22 08:30AM	Artelo Biosciences to Present at The LD Micro Main Event XV (Newsfile)
Sep-22-22 09:00AM	Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th (GlobeNewswire)
Sep-07-22 08:30AM	Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-16-22 09:00AM	Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5 (GlobeNewswire) +45.87%
Aug-09-22 08:10AM	Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -23.66%
Jul-19-22 09:07AM	Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire)
Jun-27-22 08:30AM	Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain (GlobeNewswire)
Jun-24-22 08:30AM	Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland (GlobeNewswire)
Jun-01-22 08:30AM	Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th (GlobeNewswire)
May-16-22 01:20PM	36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 (ACCESSWIRE)
08:55AM	Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th (GlobeNewswire)
May-13-22 08:30AM	Artelo Biosciences to Present at MicroCap Rodeos Spring into Action Best Ideas Virtual Conference on May 16th (ACCESSWIRE)
May-12-22 08:30AM	Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +7.69%
Apr-26-22 07:33AM	Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York (Newsfile)
Apr-25-22 07:30AM	Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York (Newsfile)
Apr-13-22 08:30AM	Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia (GlobeNewswire) +20.38%
Mar-28-22 09:25AM	Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer (GlobeNewswire) -7.34%
Mar-22-22 09:00AM	Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th 30th (GlobeNewswire)
Mar-21-22 08:30AM	Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update (GlobeNewswire) +7.27%
Mar-02-22 08:30AM	Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol (GlobeNewswire) +14.30%
Jan-12-22 08:30AM	Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jan-11-22 08:30AM	Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom (GlobeNewswire)
Jan-10-22 09:00AM	Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire) -8.00%
Jan-04-22 01:38PM	Lvm Capital Management Ltd Buys Medtronic PLC, Zoetis Inc, Eaton Corp PLC, Sells AT&T Inc, ... (GuruFocus.com)
Nov-29-21 08:30AM	Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update (GlobeNewswire) -6.95%
Nov-11-21 08:30AM	Artelo Biosciences to Present at the Q4 Investor Summit on November 17th (Newsfile) -7.45%
Nov-02-21 07:33AM	We Think Artelo Biosciences (NASDAQ:ARTL) Needs To Drive Business Growth Carefully (Simply Wall St.) +14.93%
Sep-08-21 08:30AM	Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-11-21 04:18PM	Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th (Newsfile)
Aug-04-21 08:30AM	Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines (GlobeNewswire)
Jul-21-21 08:30AM	Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences CAReS Study on July 28, 2021 (GlobeNewswire)
Jul-12-21 08:30AM	Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire)
Jul-07-21 08:30AM	Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th (GlobeNewswire) -8.55%
Jun-22-21 08:00AM	Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium (GlobeNewswire)
Jun-02-21 08:30AM	Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th (GlobeNewswire)
May-06-21 07:00AM	Artelo Biosciences to Participate at the Benzinga Global Small Cap Conference on May 13, 2021 (Newsfile)
May-04-21 08:00AM	Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors (PR Newswire) -5.84%
Apr-20-21 02:02AM	We're Hopeful That Artelo Biosciences (NASDAQ:ARTL) Will Use Its Cash Wisely (Simply Wall St.) -9.52%
Apr-13-21 08:30AM	Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire)
Apr-12-21 08:30AM	Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire) -9.21%
Mar-19-21 10:00AM	Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development (GlobeNewswire)
Mar-11-21 07:10AM	Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd (GlobeNewswire)
Mar-09-21 08:30AM	Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors (GlobeNewswire) +22.37%
Mar-02-21 08:30AM	Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th (GlobeNewswire) -6.10%
Feb-17-21 08:30AM	Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal (GlobeNewswire) +14.18%
Feb-16-21 08:30AM	Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer (GlobeNewswire)
Feb-12-21 10:56AM	ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today (InvestorPlace) +63.19%
Feb-08-21 08:30AM	Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants (GlobeNewswire) +8.47%
Feb-02-21 08:30AM	Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia (GlobeNewswire) +20.19%
Jan-29-21 04:05PM	Artelo Biosciences to Present at the LSX World Congress Virtual Conference (GlobeNewswire) +6.39% +8.60%

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARTL

Artelo Biosciences Inc

Upgrade your FINVIZ experience